Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Henry Khederian

Why Checkmate Pharmaceuticals Shares Are Skyrocketing

Checkmate Pharmaceuticals Inc (NASDAQ:CMPI) shares are trading higher by 328.40% to $10.41 during Tuesday's pre-market session after Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced a deal to acquire the company for $10.50 per share in cash.

Checkmate's lead investigational candidate is vidutolimod, an advanced generation CpG-A oligodeoxynucleotide Toll-like receptor 9 (TLR9) agonist delivered in a virus-like particle.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.